Taken together, these data suggest that targeting PHGDH with NCT-503 effectively diminishes the growth of tumors originating from GSCs and markedly bolsters the therapeutic impact of radiotherapy in GBM management. This evidence concerns the gene PHGDH and glioblastoma.